Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development

Texas-based company is designed to coordinate U.S. development, pharmaceutical-grade supply and potential clinical sponsorship activities through a dedicated Psyence BioMed entity

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company developing nature-derived neuroplastogen therapeutics, today announced the formation of Texas Ibogaine Research Corporation (“TIRC”), a Texas-based company established to coordinate the Company’s U.S. ibogaine development activities, including pharmaceutical-grade supply, regulatory engagement and potential clinical development.

A welcome email is on its way. If you don't see it, please check your junk folder.

TIRC has been established as the Company’s dedicated U.S. vehicle for the regulated development of ibogaine. Subject to completion of definitive licensing arrangements, TIRC is positioned to hold U.S. rights to pharmaceutical-grade ibogaine developed by PsyLabs, a neuroplastogen active pharmaceutical ingredient development company in which Psyence BioMed holds an ownership interest.

The Company intends for TIRC to coordinate the applicable rights, manufacturing arrangements, regulatory documentation and any future investigational new drug application within a single U.S. entity financed by Psyence BioMed. TIRC is also intended to serve as the Company’s counterparty of record in engagements with federal agencies, state programs and potential clinical partners in the United States.

Jody Aufrichtig, Chief Executive Officer of Psyence BioMed, will also serve as Chief Executive Officer of TIRC. Dr. John Thorne has been appointed project lead. Psyence BioMed expects to provide technical, legal, administrative and financial support through existing internal resources, with corporate oversight that includes Chief Financial Officer Warwick Corden-Lloyd and the Company’s in-house legal function.

“The United States is creating new momentum around rigorous, regulated ibogaine research. We established TIRC in Texas to contribute to that effort by bringing the rights, pharmaceutical-grade supply and development strategy together within a dedicated U.S. company advancing this research for U.S. patients.”

— Jody Aufrichtig, Chief Executive Officer, Psyence BioMed and Texas Ibogaine Research Corporation

“TIRC gives us a focused structure through which to coordinate the material, regulatory documentation, manufacturing pathway and clinical development plan. This positions us to engage efficiently with government agencies and potential research partners as opportunities advance.”